Skip to main content
EJNMMI Research

Table 2 Tumor targeting and normal organ distribution of i

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

 

Time points (h)

Tissue

24

48

72

96

168

Blood

6.84 ± 2.30

2.28 ± 0.53

1.12 ± 0.27

0.32 ± 0.12

0.08 ± 0.02

Tumor

21.42 ± 7.67

21.12 ± 2.85

21.55 ± 6.2

16.55 ± 2.35

8.01 ± 3.65

Liver

8.01 ± 1.63

4.98 ± 0.98

4.66 ± 0.62

3.55 ± 0.62

3.38 ± 0.67

Spleen

5.43 ± 1.64

3.61 ± 0.87

3.96 ± 1.19

2.63 ± 1.12

2.09 ± 0.80

Kidneys

13.13 ± 2.34

8.27 ± 0.84

6.00 ± 1.57

5.22 ± 0.94

2.66 ± 0.46

Lung

4.40 ± 1.14

2.23 ± 0.39

1.79 ± 0.31

1.06 ± 0.21

0.8 ± 0.26

Heart

3.57 ± 1.11

2.06 ± 0.23

1.86 ± 0.30

1.20 ± 0.21

0.78 ± 0.12

Femur

2.41 ± 0.48

1.78 ± 0.41

1.67 ± 0.24

1.01 ± 0.24

0.75 ± 0.22

  1. Athymic mice bearing s.c. LS-174T xenografts were injected with 111In- CHX-A"-panitumumab F(ab')2 (approximately 7.5 μCi). At the indicated time points, the mice (n = 5) were sacrificed by exsanguination; the tumor, blood, and major normal organs were harvested, wet-weighed, and the radioactivity measured. The values represent the average percent injected dose per gram (%ID/g) of tissue along and the standard deviations.
Back to article page